Trial · NCT05203835
A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema
NCT05203835, Phase 2, Completed, Stanford University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema. Trials, record NCT05203835. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05203835
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema
- NCT number
- NCT05203835
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 40 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Lymphedema of Upper Arm
- Interventions
- Acebilustat, Placebo
- First posted
- 2022-01-24
- Last updated
- 2026-05-28
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in cutaneous thickness in the affected upper extremity, as measured by skin calipers. | Comparison of the measurement of week 0 to week 12 and of week 12 to week 36 | Cutaneous thickness will be measured by skin calipers at three designated locations in the affected upper extremity. |
| Secondary | Change in cutaneous dimensions and architecture in the affected upper extremity, as measured by ultrasound | Comparison of the measurement of week 0 to week 12 and of week 12 to week 36 | Cutaneous measurements will be derived from serial ultrasonographic examination at three designated locations in the affected upper extremity using a Terason 3200T device |
| Secondary | Change in the volume of the affected upper extremity. | Comparison of the measurement of week 0 to week 12 and of week 12 to week 36. | Volume changes in the affected upper extremity will be calculated through circumferential measurements of the limb and quantitated with the truncated cone approximation. |
| Secondary | Change in LymQoL score | Comparison of the measurement of week 0 to week 12 and of week 12 to week 36. | Change in the LymQoL (Lymphedema Quality of Life) questionnaire score will be used to assess the impact of lymphedema on patients' quality of life. The LymQoL is a validated, disease-specific tool measuring physical, psychological, appearance, and functional domains (range 0-100; higher scores indicate worse QoL). |
| Secondary | Change in LymVAS score | Comparison of the measurement of week 0 to week 12 and of week 12 to week 36. | Change in the LymVAS (Lymphedema Visual Analog Scale) questionnaire score will be used to assess patient-perceived lymphedema severity (0 = none, 10 = worst). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05203835
GET https://conductscience.org/api/trials/v1/NCT05203835/registered